Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19

Summary

To determine if the reduction in TMPRSS2 activity via direct inhibition with Camostat mesilate combined with standard of care (SOC) treatment will increase the proportion of patients alive and free from respiratory failure at Day 28 in SARS-CoV-2 as compared to SOC treatment with placebo.

Timeline

Start

2020-07-28

Primary completion

2021-12-22

Completion

2022-01-20

Drugs

Indications